mrna expression levels Search Results


pparg mrna expression level  (CH Instruments)
90
CH Instruments pparg mrna expression level
Pparg Mrna Expression Level, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+expression+levels/pparg+mrna+expression+level/pmc11965223-200-3-13
Average 90 stars, based on 1 article reviews
pparg mrna expression level - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anti–human epidermal growth factor receptor (her)-2 treatments  (Alphamed INC)
90
Alphamed INC anti–human epidermal growth factor receptor (her)-2 treatments
Anti–Human Epidermal Growth Factor Receptor (Her) 2 Treatments, supplied by Alphamed INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+expression+levels/her2+erbb2+mrna+expression+level/pm18650259-17-17-0
Average 90 stars, based on 1 article reviews
anti–human epidermal growth factor receptor (her)-2 treatments - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mrna expression levels of b1, b2 and b5 subunit  (CEM Corporation)
90
CEM Corporation mrna expression levels of b1, b2 and b5 subunit
Mrna Expression Levels Of B1, B2 And B5 Subunit, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+expression+levels/mrna+expression+levels+of+b1++b2+and+b5+subunit/pm21941364-73-109-113
Average 90 stars, based on 1 article reviews
mrna expression levels of b1, b2 and b5 subunit - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
gimap genes mrna expression levels  (CEM Corporation)
90
CEM Corporation gimap genes mrna expression levels
Gimap Genes Mrna Expression Levels, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+expression+levels/gimap+genes+mrna+expression+levels/pmc09890034__2022_280761_LIM_SUPPL-36-14-38
Average 90 stars, based on 1 article reviews
gimap genes mrna expression levels - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
shrna  (CEM Corporation)
90
CEM Corporation shrna
The combination of CX-4945 and WDR5 disruption has a synergistic antileukemic effect in the T-ALL mice model. (A) Schematic representation of the human T-ALL CEM cell-xenograft mouse model (CEM xenograft). CEM (2 × 10 5 per mouse) were IV injected into NCG mice, and the following 4 groups of mice were established: group 1 (vehicle control); group 2 (CX-4945 daily through gavage at 100 mg/kg for 25 days); group 3 (WDR5 inhibitor OICR-9429 every 2 days through intraperitoneal injection at 60 mg/kg for 25 days); and group 4 (CX-4945 and OICR-9429 combination treatment using the same doses as provided previously). (B) Comparison of Kaplan-Meier survival curves in the combination of CX-4945 and WDR5 inhibitor OICR-9429 compared with either single drug control of CEM-xenograft mouse models. The mice were treated with the indicated drugs for 25 days. (C-D) Spleen images (C) and weights (D) of 4 groups of mice posttreatment. (E) The percentage of human CD45 + and CD7 + cells in the spleen and BM from 4 groups of mice post-treatment. (F-G) Representative immunohistological images (F) and quantitation data (G) of human CD45 in the spleen from 4 groups of mice post-treatment. (H) The protein level of WDR5 and <t>ATAD2</t> and the internal control of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the spleen tissues of the mice after the treatment. (I) mRNA level of WDR5 , ATAD2 , CCNE2 , and CDK2 in the spleen tissues of the mice after the treatment. Scale bar, 50 μm. ∗∗∗ P < .001. i.g., intragastic gavage; i.p., intraperitoneal injection; OI, OICR-9429.
Shrna, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+expression+levels/atad2+expression+in+mrna+level/pmc11969266-159-15-28
Average 90 stars, based on 1 article reviews
shrna - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mrna expression levels of genes  (Allen Institute for Brain Science)
90
Allen Institute for Brain Science mrna expression levels of genes
The combination of CX-4945 and WDR5 disruption has a synergistic antileukemic effect in the T-ALL mice model. (A) Schematic representation of the human T-ALL CEM cell-xenograft mouse model (CEM xenograft). CEM (2 × 10 5 per mouse) were IV injected into NCG mice, and the following 4 groups of mice were established: group 1 (vehicle control); group 2 (CX-4945 daily through gavage at 100 mg/kg for 25 days); group 3 (WDR5 inhibitor OICR-9429 every 2 days through intraperitoneal injection at 60 mg/kg for 25 days); and group 4 (CX-4945 and OICR-9429 combination treatment using the same doses as provided previously). (B) Comparison of Kaplan-Meier survival curves in the combination of CX-4945 and WDR5 inhibitor OICR-9429 compared with either single drug control of CEM-xenograft mouse models. The mice were treated with the indicated drugs for 25 days. (C-D) Spleen images (C) and weights (D) of 4 groups of mice posttreatment. (E) The percentage of human CD45 + and CD7 + cells in the spleen and BM from 4 groups of mice post-treatment. (F-G) Representative immunohistological images (F) and quantitation data (G) of human CD45 in the spleen from 4 groups of mice post-treatment. (H) The protein level of WDR5 and <t>ATAD2</t> and the internal control of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the spleen tissues of the mice after the treatment. (I) mRNA level of WDR5 , ATAD2 , CCNE2 , and CDK2 in the spleen tissues of the mice after the treatment. Scale bar, 50 μm. ∗∗∗ P < .001. i.g., intragastic gavage; i.p., intraperitoneal injection; OI, OICR-9429.
Mrna Expression Levels Of Genes, supplied by Allen Institute for Brain Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+expression+levels/mrna+expression+levels+of+genes/pmc09326261-128-2-11
Average 90 stars, based on 1 article reviews
mrna expression levels of genes - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
gstp1 mrna expression levels  (Response Genetics Inc)
90
Response Genetics Inc gstp1 mrna expression levels
The combination of CX-4945 and WDR5 disruption has a synergistic antileukemic effect in the T-ALL mice model. (A) Schematic representation of the human T-ALL CEM cell-xenograft mouse model (CEM xenograft). CEM (2 × 10 5 per mouse) were IV injected into NCG mice, and the following 4 groups of mice were established: group 1 (vehicle control); group 2 (CX-4945 daily through gavage at 100 mg/kg for 25 days); group 3 (WDR5 inhibitor OICR-9429 every 2 days through intraperitoneal injection at 60 mg/kg for 25 days); and group 4 (CX-4945 and OICR-9429 combination treatment using the same doses as provided previously). (B) Comparison of Kaplan-Meier survival curves in the combination of CX-4945 and WDR5 inhibitor OICR-9429 compared with either single drug control of CEM-xenograft mouse models. The mice were treated with the indicated drugs for 25 days. (C-D) Spleen images (C) and weights (D) of 4 groups of mice posttreatment. (E) The percentage of human CD45 + and CD7 + cells in the spleen and BM from 4 groups of mice post-treatment. (F-G) Representative immunohistological images (F) and quantitation data (G) of human CD45 in the spleen from 4 groups of mice post-treatment. (H) The protein level of WDR5 and <t>ATAD2</t> and the internal control of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the spleen tissues of the mice after the treatment. (I) mRNA level of WDR5 , ATAD2 , CCNE2 , and CDK2 in the spleen tissues of the mice after the treatment. Scale bar, 50 μm. ∗∗∗ P < .001. i.g., intragastic gavage; i.p., intraperitoneal injection; OI, OICR-9429.
Gstp1 Mrna Expression Levels, supplied by Response Genetics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+expression+levels/gstp1+mrna+expression+levels/10__1158_slash_1078___0432__ccr___14___0857-72-0-7
Average 90 stars, based on 1 article reviews
gstp1 mrna expression levels - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mrna expression levels of vc  (Alphamed INC)
90
Alphamed INC mrna expression levels of vc
The combination of CX-4945 and WDR5 disruption has a synergistic antileukemic effect in the T-ALL mice model. (A) Schematic representation of the human T-ALL CEM cell-xenograft mouse model (CEM xenograft). CEM (2 × 10 5 per mouse) were IV injected into NCG mice, and the following 4 groups of mice were established: group 1 (vehicle control); group 2 (CX-4945 daily through gavage at 100 mg/kg for 25 days); group 3 (WDR5 inhibitor OICR-9429 every 2 days through intraperitoneal injection at 60 mg/kg for 25 days); and group 4 (CX-4945 and OICR-9429 combination treatment using the same doses as provided previously). (B) Comparison of Kaplan-Meier survival curves in the combination of CX-4945 and WDR5 inhibitor OICR-9429 compared with either single drug control of CEM-xenograft mouse models. The mice were treated with the indicated drugs for 25 days. (C-D) Spleen images (C) and weights (D) of 4 groups of mice posttreatment. (E) The percentage of human CD45 + and CD7 + cells in the spleen and BM from 4 groups of mice post-treatment. (F-G) Representative immunohistological images (F) and quantitation data (G) of human CD45 in the spleen from 4 groups of mice post-treatment. (H) The protein level of WDR5 and <t>ATAD2</t> and the internal control of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the spleen tissues of the mice after the treatment. (I) mRNA level of WDR5 , ATAD2 , CCNE2 , and CDK2 in the spleen tissues of the mice after the treatment. Scale bar, 50 μm. ∗∗∗ P < .001. i.g., intragastic gavage; i.p., intraperitoneal injection; OI, OICR-9429.
Mrna Expression Levels Of Vc, supplied by Alphamed INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+expression+levels/mrna+expression+levels+of+vc/pm27018646-159-11-12
Average 90 stars, based on 1 article reviews
mrna expression levels of vc - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mtdh mrna relative expression level  (CH Instruments)
90
CH Instruments mtdh mrna relative expression level
The combination of CX-4945 and WDR5 disruption has a synergistic antileukemic effect in the T-ALL mice model. (A) Schematic representation of the human T-ALL CEM cell-xenograft mouse model (CEM xenograft). CEM (2 × 10 5 per mouse) were IV injected into NCG mice, and the following 4 groups of mice were established: group 1 (vehicle control); group 2 (CX-4945 daily through gavage at 100 mg/kg for 25 days); group 3 (WDR5 inhibitor OICR-9429 every 2 days through intraperitoneal injection at 60 mg/kg for 25 days); and group 4 (CX-4945 and OICR-9429 combination treatment using the same doses as provided previously). (B) Comparison of Kaplan-Meier survival curves in the combination of CX-4945 and WDR5 inhibitor OICR-9429 compared with either single drug control of CEM-xenograft mouse models. The mice were treated with the indicated drugs for 25 days. (C-D) Spleen images (C) and weights (D) of 4 groups of mice posttreatment. (E) The percentage of human CD45 + and CD7 + cells in the spleen and BM from 4 groups of mice post-treatment. (F-G) Representative immunohistological images (F) and quantitation data (G) of human CD45 in the spleen from 4 groups of mice post-treatment. (H) The protein level of WDR5 and <t>ATAD2</t> and the internal control of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the spleen tissues of the mice after the treatment. (I) mRNA level of WDR5 , ATAD2 , CCNE2 , and CDK2 in the spleen tissues of the mice after the treatment. Scale bar, 50 μm. ∗∗∗ P < .001. i.g., intragastic gavage; i.p., intraperitoneal injection; OI, OICR-9429.
Mtdh Mrna Relative Expression Level, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+expression+levels/mtdh+mrna+relative+expression+level/10__1016_slash_j__ejmhg__2018__02__002-113-44-62
Average 90 stars, based on 1 article reviews
mtdh mrna relative expression level - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
32p-labeled human rfc1 cdna probe  (CEM Corporation)
90
CEM Corporation 32p-labeled human rfc1 cdna probe
The combination of CX-4945 and WDR5 disruption has a synergistic antileukemic effect in the T-ALL mice model. (A) Schematic representation of the human T-ALL CEM cell-xenograft mouse model (CEM xenograft). CEM (2 × 10 5 per mouse) were IV injected into NCG mice, and the following 4 groups of mice were established: group 1 (vehicle control); group 2 (CX-4945 daily through gavage at 100 mg/kg for 25 days); group 3 (WDR5 inhibitor OICR-9429 every 2 days through intraperitoneal injection at 60 mg/kg for 25 days); and group 4 (CX-4945 and OICR-9429 combination treatment using the same doses as provided previously). (B) Comparison of Kaplan-Meier survival curves in the combination of CX-4945 and WDR5 inhibitor OICR-9429 compared with either single drug control of CEM-xenograft mouse models. The mice were treated with the indicated drugs for 25 days. (C-D) Spleen images (C) and weights (D) of 4 groups of mice posttreatment. (E) The percentage of human CD45 + and CD7 + cells in the spleen and BM from 4 groups of mice post-treatment. (F-G) Representative immunohistological images (F) and quantitation data (G) of human CD45 in the spleen from 4 groups of mice post-treatment. (H) The protein level of WDR5 and <t>ATAD2</t> and the internal control of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the spleen tissues of the mice after the treatment. (I) mRNA level of WDR5 , ATAD2 , CCNE2 , and CDK2 in the spleen tissues of the mice after the treatment. Scale bar, 50 μm. ∗∗∗ P < .001. i.g., intragastic gavage; i.p., intraperitoneal injection; OI, OICR-9429.
32p Labeled Human Rfc1 Cdna Probe, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+expression+levels/mrna+expression+level+of+rfc1/pm09804775-78-12-24
Average 90 stars, based on 1 article reviews
32p-labeled human rfc1 cdna probe - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
relative hint1 mrna expression levels  (CEM Corporation)
90
CEM Corporation relative hint1 mrna expression levels
The combination of CX-4945 and WDR5 disruption has a synergistic antileukemic effect in the T-ALL mice model. (A) Schematic representation of the human T-ALL CEM cell-xenograft mouse model (CEM xenograft). CEM (2 × 10 5 per mouse) were IV injected into NCG mice, and the following 4 groups of mice were established: group 1 (vehicle control); group 2 (CX-4945 daily through gavage at 100 mg/kg for 25 days); group 3 (WDR5 inhibitor OICR-9429 every 2 days through intraperitoneal injection at 60 mg/kg for 25 days); and group 4 (CX-4945 and OICR-9429 combination treatment using the same doses as provided previously). (B) Comparison of Kaplan-Meier survival curves in the combination of CX-4945 and WDR5 inhibitor OICR-9429 compared with either single drug control of CEM-xenograft mouse models. The mice were treated with the indicated drugs for 25 days. (C-D) Spleen images (C) and weights (D) of 4 groups of mice posttreatment. (E) The percentage of human CD45 + and CD7 + cells in the spleen and BM from 4 groups of mice post-treatment. (F-G) Representative immunohistological images (F) and quantitation data (G) of human CD45 in the spleen from 4 groups of mice post-treatment. (H) The protein level of WDR5 and <t>ATAD2</t> and the internal control of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the spleen tissues of the mice after the treatment. (I) mRNA level of WDR5 , ATAD2 , CCNE2 , and CDK2 in the spleen tissues of the mice after the treatment. Scale bar, 50 μm. ∗∗∗ P < .001. i.g., intragastic gavage; i.p., intraperitoneal injection; OI, OICR-9429.
Relative Hint1 Mrna Expression Levels, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+expression+levels/relative+hint1+mrna+expression+levels/pmc02966047-530-1-10
Average 90 stars, based on 1 article reviews
relative hint1 mrna expression levels - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mrna expression level analysis  (CapitalBio Corporation)
90
CapitalBio Corporation mrna expression level analysis
The combination of CX-4945 and WDR5 disruption has a synergistic antileukemic effect in the T-ALL mice model. (A) Schematic representation of the human T-ALL CEM cell-xenograft mouse model (CEM xenograft). CEM (2 × 10 5 per mouse) were IV injected into NCG mice, and the following 4 groups of mice were established: group 1 (vehicle control); group 2 (CX-4945 daily through gavage at 100 mg/kg for 25 days); group 3 (WDR5 inhibitor OICR-9429 every 2 days through intraperitoneal injection at 60 mg/kg for 25 days); and group 4 (CX-4945 and OICR-9429 combination treatment using the same doses as provided previously). (B) Comparison of Kaplan-Meier survival curves in the combination of CX-4945 and WDR5 inhibitor OICR-9429 compared with either single drug control of CEM-xenograft mouse models. The mice were treated with the indicated drugs for 25 days. (C-D) Spleen images (C) and weights (D) of 4 groups of mice posttreatment. (E) The percentage of human CD45 + and CD7 + cells in the spleen and BM from 4 groups of mice post-treatment. (F-G) Representative immunohistological images (F) and quantitation data (G) of human CD45 in the spleen from 4 groups of mice post-treatment. (H) The protein level of WDR5 and <t>ATAD2</t> and the internal control of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the spleen tissues of the mice after the treatment. (I) mRNA level of WDR5 , ATAD2 , CCNE2 , and CDK2 in the spleen tissues of the mice after the treatment. Scale bar, 50 μm. ∗∗∗ P < .001. i.g., intragastic gavage; i.p., intraperitoneal injection; OI, OICR-9429.
Mrna Expression Level Analysis, supplied by CapitalBio Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+expression+levels/mrna+expression+level+analysis/pmc08250429-160-12-16
Average 90 stars, based on 1 article reviews
mrna expression level analysis - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


The combination of CX-4945 and WDR5 disruption has a synergistic antileukemic effect in the T-ALL mice model. (A) Schematic representation of the human T-ALL CEM cell-xenograft mouse model (CEM xenograft). CEM (2 × 10 5 per mouse) were IV injected into NCG mice, and the following 4 groups of mice were established: group 1 (vehicle control); group 2 (CX-4945 daily through gavage at 100 mg/kg for 25 days); group 3 (WDR5 inhibitor OICR-9429 every 2 days through intraperitoneal injection at 60 mg/kg for 25 days); and group 4 (CX-4945 and OICR-9429 combination treatment using the same doses as provided previously). (B) Comparison of Kaplan-Meier survival curves in the combination of CX-4945 and WDR5 inhibitor OICR-9429 compared with either single drug control of CEM-xenograft mouse models. The mice were treated with the indicated drugs for 25 days. (C-D) Spleen images (C) and weights (D) of 4 groups of mice posttreatment. (E) The percentage of human CD45 + and CD7 + cells in the spleen and BM from 4 groups of mice post-treatment. (F-G) Representative immunohistological images (F) and quantitation data (G) of human CD45 in the spleen from 4 groups of mice post-treatment. (H) The protein level of WDR5 and ATAD2 and the internal control of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the spleen tissues of the mice after the treatment. (I) mRNA level of WDR5 , ATAD2 , CCNE2 , and CDK2 in the spleen tissues of the mice after the treatment. Scale bar, 50 μm. ∗∗∗ P < .001. i.g., intragastic gavage; i.p., intraperitoneal injection; OI, OICR-9429.

Journal: Blood

Article Title: Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL ∗

doi: 10.1182/blood.2024024130

Figure Lengend Snippet: The combination of CX-4945 and WDR5 disruption has a synergistic antileukemic effect in the T-ALL mice model. (A) Schematic representation of the human T-ALL CEM cell-xenograft mouse model (CEM xenograft). CEM (2 × 10 5 per mouse) were IV injected into NCG mice, and the following 4 groups of mice were established: group 1 (vehicle control); group 2 (CX-4945 daily through gavage at 100 mg/kg for 25 days); group 3 (WDR5 inhibitor OICR-9429 every 2 days through intraperitoneal injection at 60 mg/kg for 25 days); and group 4 (CX-4945 and OICR-9429 combination treatment using the same doses as provided previously). (B) Comparison of Kaplan-Meier survival curves in the combination of CX-4945 and WDR5 inhibitor OICR-9429 compared with either single drug control of CEM-xenograft mouse models. The mice were treated with the indicated drugs for 25 days. (C-D) Spleen images (C) and weights (D) of 4 groups of mice posttreatment. (E) The percentage of human CD45 + and CD7 + cells in the spleen and BM from 4 groups of mice post-treatment. (F-G) Representative immunohistological images (F) and quantitation data (G) of human CD45 in the spleen from 4 groups of mice post-treatment. (H) The protein level of WDR5 and ATAD2 and the internal control of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the spleen tissues of the mice after the treatment. (I) mRNA level of WDR5 , ATAD2 , CCNE2 , and CDK2 in the spleen tissues of the mice after the treatment. Scale bar, 50 μm. ∗∗∗ P < .001. i.g., intragastic gavage; i.p., intraperitoneal injection; OI, OICR-9429.

Article Snippet: Oncogenic roles of ATAD2 by regulating cell cycle progression in T-ALL. (A) The efficiency of ATAD2 KD by shRNA (sh ATAD2 ) vs scramble shRNA control (shNC) in CEM (left) and MOLT4 (right) cells by western blot. (B) Effect of ATAD2 KD vs shNC on cell proliferation in CEM (left) and MOLT4 (right) cells. (C-D) Effect of ATAD2 KD vs shNC on cell cycle progression in CEM cells (C, representative images; D, bar graph). (E-F) Effect of ATAD2 silence by shRNA vs shNC on Kaplan-Meier survival curves (E), and percentage of human CD45 + CD7 + cells (F) in the spleen and BM of the xenograft mouse model.

Techniques: Disruption, Injection, Control, Comparison, Quantitation Assay

Therapeutic efficacy of the combination of CX-4945 and WDR5 inhibitor in patient-derived T-ALL leukemia-xenograft (PDX) mouse model. (A) Comparison of Kaplan-Meier survival curves in the combination of CX-4945 and WDR5 inhibitor OICR-9429 compared with either single drug controls in 3 different PDX mouse models: PDX-P1 (Patient, [Pt.] T-ALL-P1 in <xref ref-type=supplemental Table 3 ), PDX-P2 (Pt. T-ALL-P2), and PDX-P3 (Pt. T-ALL-P3). (B) Comparison of percentage of human CD45 + CD7 + cells in the spleen of the mice in combo group vs either single drug controls. (C-E) Comparison of mRNA level of WDR5 , ATAD2 , CCNE2 , and CDK2 in combo group vs either single drug controls in the spleen of the mouse models. The mice in panels A-E were treated with the indicated drugs for 25 days, and then, when the vehicle mice met the early removal criteria due to the excessive leukemia burden, the mice were euthanized and the single cells were isolated from the spleen for flow cytometry analysis; the mRNA of the cells was prepared for qPCR analysis. ∗∗∗ P < .001. OI, OICR-9429. " width="100%" height="100%">

Journal: Blood

Article Title: Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL ∗

doi: 10.1182/blood.2024024130

Figure Lengend Snippet: Therapeutic efficacy of the combination of CX-4945 and WDR5 inhibitor in patient-derived T-ALL leukemia-xenograft (PDX) mouse model. (A) Comparison of Kaplan-Meier survival curves in the combination of CX-4945 and WDR5 inhibitor OICR-9429 compared with either single drug controls in 3 different PDX mouse models: PDX-P1 (Patient, [Pt.] T-ALL-P1 in supplemental Table 3 ), PDX-P2 (Pt. T-ALL-P2), and PDX-P3 (Pt. T-ALL-P3). (B) Comparison of percentage of human CD45 + CD7 + cells in the spleen of the mice in combo group vs either single drug controls. (C-E) Comparison of mRNA level of WDR5 , ATAD2 , CCNE2 , and CDK2 in combo group vs either single drug controls in the spleen of the mouse models. The mice in panels A-E were treated with the indicated drugs for 25 days, and then, when the vehicle mice met the early removal criteria due to the excessive leukemia burden, the mice were euthanized and the single cells were isolated from the spleen for flow cytometry analysis; the mRNA of the cells was prepared for qPCR analysis. ∗∗∗ P < .001. OI, OICR-9429.

Article Snippet: Oncogenic roles of ATAD2 by regulating cell cycle progression in T-ALL. (A) The efficiency of ATAD2 KD by shRNA (sh ATAD2 ) vs scramble shRNA control (shNC) in CEM (left) and MOLT4 (right) cells by western blot. (B) Effect of ATAD2 KD vs shNC on cell proliferation in CEM (left) and MOLT4 (right) cells. (C-D) Effect of ATAD2 KD vs shNC on cell cycle progression in CEM cells (C, representative images; D, bar graph). (E-F) Effect of ATAD2 silence by shRNA vs shNC on Kaplan-Meier survival curves (E), and percentage of human CD45 + CD7 + cells (F) in the spleen and BM of the xenograft mouse model.

Techniques: Drug discovery, Derivative Assay, Comparison, Isolation, Flow Cytometry

Identifying ATAD2 as the downstream target on CX-4945–mediated transcriptional repression of WDR5 in T-ALL. (A-B) Effect of WDR5 KD on ATAD2 expression in mRNA level (A) and protein level (B) of CEM (left) and MOLT4 (right) cells. (C) Overlapping DEGs from the RNA-seq data in CEM cells treated with CX-4945 or WDR5 inhibitor. (D) Heat map of the top overlapped DEGs in the 2 RNA-seq analyses. (E-F) Effect of combination of CX-4945 (CX) and WDR5 inhibitor OICR-9429 (OI) on the expression of ATAD2 compared with a single drug in mRNA level (E) and protein level (F) in CEM cells. (G) Effect of WDR5 on the activity of the ATAD2 promoter assessed by luciferase reporter assay in 293T cells. (H) Effect of WDR5 KD on the H3K4me3 enrichment in the promoter region of ATAD2 in CEM cells by qChIP assay. (I-J) Effect of CX-4945 on WDR5 binding and H3K4me3 enrichment at the ATAD2 promoter in CEM cells by qChIP assay. Panels H-J are representative of 3 qChIP assays. ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001. IgG, immunoglobulin G; OI, OICR-9429.

Journal: Blood

Article Title: Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL ∗

doi: 10.1182/blood.2024024130

Figure Lengend Snippet: Identifying ATAD2 as the downstream target on CX-4945–mediated transcriptional repression of WDR5 in T-ALL. (A-B) Effect of WDR5 KD on ATAD2 expression in mRNA level (A) and protein level (B) of CEM (left) and MOLT4 (right) cells. (C) Overlapping DEGs from the RNA-seq data in CEM cells treated with CX-4945 or WDR5 inhibitor. (D) Heat map of the top overlapped DEGs in the 2 RNA-seq analyses. (E-F) Effect of combination of CX-4945 (CX) and WDR5 inhibitor OICR-9429 (OI) on the expression of ATAD2 compared with a single drug in mRNA level (E) and protein level (F) in CEM cells. (G) Effect of WDR5 on the activity of the ATAD2 promoter assessed by luciferase reporter assay in 293T cells. (H) Effect of WDR5 KD on the H3K4me3 enrichment in the promoter region of ATAD2 in CEM cells by qChIP assay. (I-J) Effect of CX-4945 on WDR5 binding and H3K4me3 enrichment at the ATAD2 promoter in CEM cells by qChIP assay. Panels H-J are representative of 3 qChIP assays. ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001. IgG, immunoglobulin G; OI, OICR-9429.

Article Snippet: Oncogenic roles of ATAD2 by regulating cell cycle progression in T-ALL. (A) The efficiency of ATAD2 KD by shRNA (sh ATAD2 ) vs scramble shRNA control (shNC) in CEM (left) and MOLT4 (right) cells by western blot. (B) Effect of ATAD2 KD vs shNC on cell proliferation in CEM (left) and MOLT4 (right) cells. (C-D) Effect of ATAD2 KD vs shNC on cell cycle progression in CEM cells (C, representative images; D, bar graph). (E-F) Effect of ATAD2 silence by shRNA vs shNC on Kaplan-Meier survival curves (E), and percentage of human CD45 + CD7 + cells (F) in the spleen and BM of the xenograft mouse model.

Techniques: Expressing, RNA Sequencing, Activity Assay, Luciferase, Reporter Assay, Binding Assay

Oncogenic roles of ATAD2 by regulating cell cycle progression in T-ALL. (A) The efficiency of ATAD2 KD by shRNA (sh ATAD2 ) vs scramble shRNA control (shNC) in CEM (left) and MOLT4 (right) cells by western blot. (B) Effect of ATAD2 KD vs shNC on cell proliferation in CEM (left) and MOLT4 (right) cells. (C-D) Effect of ATAD2 KD vs shNC on cell cycle progression in CEM cells (C, representative images; D, bar graph). (E-F) Effect of ATAD2 silence by shRNA vs shNC on Kaplan-Meier survival curves (E), and percentage of human CD45 + CD7 + cells (F) in the spleen and BM of the xenograft mouse model. The mice were IV injected with the CEM-shNC or CEM-sh ATAD2 cells, respectively, for 28 days, and the single cells were prepared and analyzed. (G) Comparison of ATAD2 mRNA level in our T-ALL cohorts vs normal BM controls. The mRNA levels were determined by qPCR assay. (H) Association of ATAD2 expression with relapse in our cohort. (I) Comparison of ATAD2 mRNA levels in 5 pairs of T-ALL newly diagnosed samples vs relapsed ones. ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001.

Journal: Blood

Article Title: Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL ∗

doi: 10.1182/blood.2024024130

Figure Lengend Snippet: Oncogenic roles of ATAD2 by regulating cell cycle progression in T-ALL. (A) The efficiency of ATAD2 KD by shRNA (sh ATAD2 ) vs scramble shRNA control (shNC) in CEM (left) and MOLT4 (right) cells by western blot. (B) Effect of ATAD2 KD vs shNC on cell proliferation in CEM (left) and MOLT4 (right) cells. (C-D) Effect of ATAD2 KD vs shNC on cell cycle progression in CEM cells (C, representative images; D, bar graph). (E-F) Effect of ATAD2 silence by shRNA vs shNC on Kaplan-Meier survival curves (E), and percentage of human CD45 + CD7 + cells (F) in the spleen and BM of the xenograft mouse model. The mice were IV injected with the CEM-shNC or CEM-sh ATAD2 cells, respectively, for 28 days, and the single cells were prepared and analyzed. (G) Comparison of ATAD2 mRNA level in our T-ALL cohorts vs normal BM controls. The mRNA levels were determined by qPCR assay. (H) Association of ATAD2 expression with relapse in our cohort. (I) Comparison of ATAD2 mRNA levels in 5 pairs of T-ALL newly diagnosed samples vs relapsed ones. ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001.

Article Snippet: Oncogenic roles of ATAD2 by regulating cell cycle progression in T-ALL. (A) The efficiency of ATAD2 KD by shRNA (sh ATAD2 ) vs scramble shRNA control (shNC) in CEM (left) and MOLT4 (right) cells by western blot. (B) Effect of ATAD2 KD vs shNC on cell proliferation in CEM (left) and MOLT4 (right) cells. (C-D) Effect of ATAD2 KD vs shNC on cell cycle progression in CEM cells (C, representative images; D, bar graph). (E-F) Effect of ATAD2 silence by shRNA vs shNC on Kaplan-Meier survival curves (E), and percentage of human CD45 + CD7 + cells (F) in the spleen and BM of the xenograft mouse model.

Techniques: shRNA, Control, Western Blot, Injection, Comparison, Expressing